Waystar Weighs Sale Options Amid Market Downturn
Waystar is considering a sale, two years after going public, amid a market slump.
Healthcare software provider Waystar is reportedly exploring strategic options, including a potential sale, according to sources familiar with the matter. This development comes just two years after the company went public in New York. Waystar, which offers technology solutions to automate and manage administrative tasks for hospitals and doctors, has engaged investment bank Evercore to guide the process. However, the discussions are in the early stages, and a sale is not guaranteed.
Market Pressures Prompt Strategic Review
Waystar's decision to explore a sale is influenced by a significant decline in its stock value, which has dropped by 24% this year, reducing its market capitalization to approximately $4.8 billion. This slump is part of a broader downturn affecting the software sector. The company had initially positioned itself as a technology firm, focusing on automation to secure higher valuations typical of tech companies. Despite a peak share price of $45 in 2025, investor concerns about potential disruptions from advances in artificial intelligence have pressured the stock.
Investment Background and Stakeholders
Waystar was formed in 2017 through the merger of Zirmed and Navicure, both healthcare revenue management companies. Its major investors include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, which took the company public in 2024. Currently, EQT holds a 13% stake, CPPIB 10%, and BlackRock Institutional Trust Company 8%, according to data from LSEG. None of these stakeholders have commented on the potential sale.
Uncertain Future and Market Dynamics
The potential sale of Waystar could serve as a barometer for investor interest in software companies amid current market conditions. While the company has not publicly commented on the sale process, the outcome could significantly impact its future operations and market positioning. Evercore, the advisory firm hired for the process, has also not provided a statement regarding the ongoing review.
The healthcare software sector, known for its rapid technological advancements, faces increasing pressure from AI developments, which could alter market dynamics. As Waystar navigates these challenges, its strategic decisions will likely shape its path in a competitive industry.